Background/Aims: In the present study, we investigated whether schisantherin A (StA) had anti-inflammatory effects under neuroinflammatory conditions. Methods: The effects of StA and its underlying mechanisms were examined in lipopolysaccharide (LPS)-activated BV-2 microglial cells by ELISA, qPCR, EMSA, Western blot, and IHC. Results: Firstly, we found that StA inhibited the inflammatory response in LPS-activated BV-2 microglia. Secondly, we found that StA suppressed LPS-induced activation of NF-κB via interfering with degradation of IκB and phosphorylation of IκB, IKK, PI3K/Akt, JNK, and p38 MAPK. Thirdly, StA conferred indirect antioxidative effects via quenching ROS and promoted expression of antioxidant enzymes, including HO-1 and NQO-1, via stimulating activation of Nrf2 pathways. Finally, we demonstrated that anti-neuroinflammatory actions of StA were dependent on ERK phosphorylation-mediated Nrf2 activation. Conclusion: StA induced ERK phosphorylationmediated Nrf2 activation, which contributed to its anti-inflammation and anti-oxidation. The anti-neuroinflammatory and anti-oxidative effects of StA may show preventive therapeutic potential for various neuroinflammatory disorders.
Introduction
Neuroinflammation is an inevitable and important pathological process involved in all types of damage and disorders in the brain [1] . Microglia, which serve as immunesurveillance cells, are well-established major components of neuroinflammatory responses in the central nervous system (CNS) [1, 2] . In response to stimuli, microglial cells can be Real-Time PCR System (Applied Biosystems Inc., Foster City, CA, USA). The amplification parameters used here were 50 °C for 2 min then 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 30 s. Each sample was analysed in triplicate, and the relative expression of mRNA was calculated after normalisation to GAPDH. The primer sequences used are also listed: iNOS forward, 5'-CAAGAGTTTGACCAGAGGACC-3'; reverse, 5'-TGGAACCACTCGTACTTGGGA-3'; COX-2 forward, 5'-TTGAAGACCAGGAGTACAGC-3'; reverse, 5'-GGTACAGTTCCATGACATCG-3'; TNF-α forward, 5'-CCTATGTCTCAGCCTCTTCT-3'; reverse, 5'-CCTGGTATGAGATAGCAAAT-3'; IL-1β forward, 5'-GGCAACTGTTCCTGAACTCAACTG-3'; reverse, 5'-CCATTGAGGTGGAGAGCTTTCAGC-3'; IL-6 forward, 5'-CCACTTCACAAGTCGGAGGCTT-3'; reverse, 5'-CCAGCTTATCTGTTAGGAGA-3'; IL-10 forward, 5'-GCCAGTACAGCCGGGAAGACAATA-3'; reverse, 5'-GCCTTGTAGACACCTTGGTCTT-3'; HO-1 forward, 5'-TGTCACCCTGTGCTTGACCT-3'; reverse, 5'-ATACCCGCTACCTGGGTGAC-3'; NQO1 forward, 5'-AGAGGCTCTGAAGAAGAGAGG-3'; reverse, 5'-CACCCTGAAGAGAGTACATGG-3';β-actin forward, 5'-AGCCATGTACGTAGCCATCC-3'; reverse, 5'-GCTGTGGTGGTGAAGCTGTA-3'; GAPDH forward, 5'-ATGTACGTAGCCATCCAGGC-3'; reverse, 5'-AGGAAGGAAGGCTGGAAGAG-3'.
Reporter gene luciferase assays
Briefly, BV-2 cells were transfected using the pARE-luc and pNFκB-luc reporter plasmid provided by the Cignal Antioxidant Response Reporter (luc) Kit and Cignal NFκB Reporter (luc) Kit, respectively, using the Attractene Transfection Reagent according to the manufacturer's protocol. Transfection efficiency was controlled by co-transfection of Renilla luciferase reporter plasmid. About 24 h after transfection, the transfected cells were subjected to further treatment. The samples were then analyzed using the DualLuciferase® Reporter Assay System, and luciferase activities were measured.
Transient transfection and siRNA knockdown BV-2 cells with a confluence of 70 to 80% were transfected with Nrf2 siRNA (80 nM, Santa Cruz), ERK siRNA (100nM, Cell Signaling Technology), or scrambled-control siRNA (Santa Cruz), using RNA iMAX kit according to specified protocols. Further experiments were performed at 24 or 36 h after transfection.
Preparation of whole cell, cytoplasmic, and nuclear protein
For the whole cell protein extraction, BV-2 cells were incubated with RIPA lysis buffer (Beyotime) and cell lysates were then centrifuged and the supernatant was collected and stored. Subcellular fractionation was done using the Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime) according to the protocol of nuclear extraction kit manufacturer. The protein content was assayed using the BCA protein quantification kit (Pierce).
Western blot analysis
Aliquots of protein samples (~30 μg) were resolved by SDS-PAGE (7.5% -15%) and transferred to PVDF membranes. Membranes were blocked, followed by incubation at 4 °C overnight with diluted primary antibodies. Membranes were washed and incubated with HRP-linked secondary antibody for 1 h at room temperature. Finally, bands were visualised using an ECLplus Western Blotting Detection Reagents kit (GE Healthcare). The membranes were then scanned on a Bio-Rad ChemiDoc XRS Imaging System, and the intensity of the protein bands was analysed using Bio-Rad Quantity One Software (Bio-Rad, Hercules, CA, USA).
Electrophoretic mobility shift assay (EMSA)
The DNA binding activity of NF-κB was analyzed using an ELISA-based TransAM NF-κB p65 EMSA kit (ActiveMotif, CA, USA) according to the manufacturer's protocol. Absorbance at 450 nm was measured. Graphing and statistical analysis Statistical analyses were performed using GraphPad Prism software (ver. 6.0; GraphPad Software Inc., San Diego, CA, USA), and data are represented as means ± standard error of the mean (SEM). Statistical analysis of differences between two groups was done using the independent-samples t-test and one-way or two-way ANOVA with Bonferroni's correction was used for multiple group comparisons. Pearson's correlation coefficient was used for correlation analyses. P < 0.05 was considered as statistically significant in all analyses.
Results

Effects of StA on the cell viability of BV-2 microglia with/without LPS stimulation
In order to estimate the range of effective concentrations, we firstly assessed the effect of StA on the cell viability of BV-2 cells. As shown in Fig. 1A and C, StA (0.1 to 50 μM) had no cytotoxic effect on BV-2 cells for 12 or 24 h incubations (all p > 0.01). LPS (500 ng/mL) treatment for 12 and 24 h slightly decreased the cell viability to 93.0 ± 4.3 %, and 90.8 ± 5.2 %, respectively, with no significant difference compared to the control group ( Fig. 1B and D , p > 0.05). However, treatment with both StA (2.5 to 50 μM) and LPS also did not affect cell viability of BV-2 cells for 12 and 24 h (Fig. 1B and D , p > 0.05).
StA showed anti-neuroinflammatory effects in LPS-activated BV-2 microglial cells
We initially evaluated the effects of StA on NO and PGE 2 production, and the expression of iNOS and COX-2, in LPS-stimulated BV-2 cells. As illustrated in Fig. 2A , pretreatment with StA for 1 h markedly decreased LPS-induced NO increases in a concentration-dependent manner (all p < 0.05, versus the LPS-treated group). Then, we found that LPS-induced expression of iNOS was also significantly inhibited by StA treatment in a concentration-dependent manner (Fig. 2B) . The best inhibitory effect was found at the dose of 50 μM, at which the levels of NO and iNOS decreased to less than 50 % of that in the LPS-treated group ( Fig. 2A and B) . Our data further showed that StA (50 μM) did not confer a time-dependent inhibitory action on NO production or iNOS expression ( Fig. 2C and D) . There was no significant difference in inhibitory action between 1, 2, 4, and 8 h of pretreatment of StA ( Fig. 2C and D, all P > 0.05). Correspondingly, pretreatment with StA (50 μM) for 1 h inhibited production of NO and PGE 2 ( Fig. 2E) , and increased expression of iNOS and COX-2 in mRNA and protein induced by LPS ( Fig. 2F and G, all p < 0.01 versus the LPS-treated group). Hence, preincubation of 50 μM StA for 1 h was used in further experiments in the current study ( Fig. 2E-G) .
Concurrently, we investigated the effects of StA on pro-inflammatory cytokines in LPSactivated BV-2 microglial cells. As shown in Fig. 3A , B and C, the LPS-induced increases in the mRNA expression of TNF-α, IL-6, and IL-1β were significantly decreased following StA treatment. Moreover, StA also markedly suppressed the protein expression of TNF-α, IL-6, and IL-1β in LPS-activated BV-2 microglia (Fig. 3E, F 
StA inhibited activation of the NF-κB pathway in LPS-activated BV-2 microglial cells
To explore the role of StA in NF-κB activation and NF-κB-regulated gene transcription and signal transduction, the NF-κB luciferase reporter system was used in current study. The results indicated that StA could inhibit the NF-κB-driven gene transcription activity increased by LPS stimulation in a dose-dependent fashion (Fig. 4A , all p < 0.01 versus the LPS-treated group). Notably, treatment with 50 μM StA significantly decreased NF-κB transactivation to ~ 42.67 % of that of the LPS-treated group (p < 0.01).
NF-κB is activated by phosphorylation, which triggers NF-κB nuclear translocation and promotes pro-inflammatory gene expression. Here, we then found that StA could significantly decrease the increase of NF-κB p65 phosphorylation in LPS-stimulated BV-2 cells (Fig. 4B , p < 0.01). Next, we examined StA's effects on nuclear translocation of the NF-κB p65 subunit. As shown in Fig. 4C , treatment with 50 μM StA significantly blocked the NF-κB p65 LPS-activated nuclear translocation, to ~ 43.2 % of that of the LPS-treated group ( Fig.  4C and 4D , p < 0.01). Nuclear translocation was further revealed by immunofluorescence assay (Fig. 4E) . As expected, StA significantly alleviated the LPS-stimulated accumulation of NF-κB p65 in the nucleus (Fig. 4E) . Followed by nuclear translocation, NF-κB p65 binds to its target DNA and triggers the transcription of pro-inflammatory genes. The ELISA-based EMSA was conducted to assess the binding of NF-κB to DNA, and current results showed that StA significantly abolished the LPS-induced NF-κB-DNA binding activity (Fig. 4F , p < 0.01).
Next, we found that LPS obviously boosted the levels of phosphorylated IKKα/β and IκBα in BV-2 microglia (Fig. 4G and 4H , p < 0.01 versus the control). However, StA significantly decreased the increased phosphorylation of IKKα/β and IκBα ( Fig. 4G and 4H , p < 0.01 versus the LPS-treated group). In addition, LPS significantly induced IκBα degradation in BV-2 cells (Fig. 4H , p < 0.001, versus the control group), which was reversed by StA treatment (Fig. 4H , p < 0.01 versus the LPS-treated group). BV-2 cells were pretreated with StA (50 μM), and then exposed to LPS (500 ng/mL) for another 12 h. (E, F, G and H) BV-2 cells were pretreated with StA (50 μM) for 2 h and then incubated with LPS for 12 h. NO and PGE 2 production in the culture medium was measured via Griess reagent and ELISA. iNOS and COX-2 protein levels were measured via Western Blot. The mRNA expression of iNOS and COX-2 was analysed by qPCR. Data are presented as means ± SEM of five independent experiments in triplicate. Control group was untreated cells. # P < 0.05 and ## P < 0.01 versus control group; * P < 0.05 and **P < 0.01, versus LPS-treated group. n.s., no significant difference among groups.
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Cellular Physiology and Biochemistry Control group was untreated cells. # P < 0.05 and ## P < 0.01 versus control group; * P < 0.05 and **P < 0.01, versus LPS-treated group. "n.s.", no significant difference among these groups. 
Effects of StA on LPS-induced phosphorylation of MAPKs and PI3K/AKT in BV-2 microglial cells
In order to further investigate StA's effects on signaling pathways involving in NF-κB activation, we next examined the phosphorylation levels of MAPKs and PI3K/Akt. We found that StA could significantly suppress LPS-induced phosphorylation of p38 (Fig. 5A) , JNK (Fig. 5C ), and Akt (Fig. 5D) , respectively (all p < 0.01 versus the LPS-treated group). Notably, StA did not alleviate the LPS-induced increase in phosphorylation of ERK (Fig. 5B , p > 0.05 versus the LPS-treated group), but StA significantly promoted the ERK phosphorylation in BV-2 cells without LPS stimulation (Fig. 5B , p < 0.01, versus the control group).
StA suppressed ROS production and NADPH oxidase subunits expression, but enhanced antioxidant enzymes, HO-1 and NQO-1 expression in LPS-activated BV-2 microglial cells
Intracellular ROS acts as an important second messenger in microglial inflammation. Hence, we next tested the role of StA in LPS-induced ROS production. Our results demonstrated that LPS stimulation obviously increased ROS production ( Fig. 6A and 6B , p < 0.01, versus the control group), whereas treatment with StA significantly decreased the ROS (Fig. 6A , all p < 0.01 versus the LPS-treated group). We also found that StA significantly suppressed LPSelevated level of phosphorylated p47phox (Fig. 6C , p < 0.01 versus the LPS-treated group).
we next examined the levels of HO-1 and NQO-1 in StA-treated BV-2 microglia. As shown in Fig. 6D and 6E, StA significantly enhanced the HO-1 and NQO-1 expression in LPS-activated BV-2 microglia in a dose-dependent fashion (all p < 0.01, versus LPS-treated group). We then used the HO-1-specific inhibitor, ZnPP to inhibit HO-1 activity and tested the role of StAinduced HO-1 expression in LPS-stimulated neuroinflammatory responses. As expected, pretreatment with ZnPP significantly abolished StA-mediated inhibition of NO, PGE 2 , TNF-α, and IL-6, respectively ( Fig. 6F and G, all p < 0.01, between the ZnPP-untreated group and ZnPP-treated group).
StA induced activation of the Nrf2 antioxidant signalling pathway in LPS-activated BV-2 microglial cells
Encouraged by the elevated level of HO-1 and NQO-1 induced by StA, we further investigated the role of StA in Nrf2-related antioxidant pathways. Firstly, as shown in Fig.  7A , we found that treatment with StA could significantly induce the accumulation of nucleus Nrf2 in a dose-dependent fashion in BV-2 cells without LPS stimulation (all p < 0.01, versus the control group). Moreover, StA could significantly enhance the Nrf2 nucleus accumulation in LPS-activated BV-2 microglia when compared to the cells without LPS stimulation (Fig.  7A , p < 0.01). Furthermore, we found that StA-mediated enhancement of the accumulation of nucleus Nrf2 was time-dependent (Fig. 7B , all p < 0.01). As illustrated in Fig. 7B , the level The levels of NO, PGE 2 , TNF-α, and IL-6 were then measured. Data are presented as means ± SEM of five independent experiments in triplicate. Control group was untreated cells. # P < 0.05 and ## P < 0.01 versus control group; * P < 0.05 and **P < 0.01, versus LPS-treated group. Two columns sharing the same letter (a and b) are significantly different (P < 0.05).
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Cellular Physiology and Biochemistry of nuclear Nrf2 was significantly increased at 1 h after StA administration, peaked at 3 to 6 h, and then declined at about 12 h. As expected, we then found that incubation of 50 μM StA for 6 h could significantly enhance both total and phosphorylated Nrf2 levels in the nuclei of BV-2 cells (Fig. 7C , all p < 0.01). Then, results of immunofluorescence clearly showed that Nrf2 was enhanced in the nucleus (Fig. 7D) . We next measured the activity of StA in antioxidant responsive elements by using a luciferase reporter containing the ARE consensus. The results of the ARE reporter assay showed that StA resulted in a dose-dependent increase of ARE-luciferase activity in both control and LPS-activated BV-2 microglial cells (Fig. 7E , all p < 0.01, versus the control group).
StA-mediated anti-neuroinflammatory action was dependent on Nrf2 activation in LPSactivated BV-2 microglial cells
We next used siRNA to silence Nfr2 expression in BV-2 microglial cells. We found that StA could also induce a significant accumulation of nuclear Nrf2 in the control siRNA group (Fig. 8A, p < 0.01) . However, StA was not able to induce Nrf2 nuclear translocation in Nrf2 siRNA-transfected BV-2 cells (Fig. 8A , p > 0.05, versus the control siRNA group). Moreover, StA-induced expression of HO-1 and NQO-1 was remarkably abolished by Nrf2 siRNA transfection (Fig. 8B , all p < 0.01 versus the control siRNA group). In addition, inhibitory actions of StA on ROS accumulation were totally abolished in Nrf2 siRNA-transfected BV-2 cells (Fig. 8C , all p < 0.01 versus the control siRNA group). Furthermore, we also found that Nrf2 knockdown significantly abrogated StA-mediated inhibition of the production of proinflammatory mediators and cytokines, including NO (Fig. 8D) , TNF-α (Fig. 8E) , and IL-6 ( Fig.  8F ) (all p < 0.01, versus the control-siRNA group). Moreover, to some extent, Nrf2 siRNAtransfection also suppressed StA-induced inhibitory effects on NF-κB reporter luciferases activity (Fig. 8G) and NF-κB-DNA binding activity (Fig. 8H) (p < 0.01, versus the control siRNA group). 
StA-induced activation of Nrf2 was mediated by ERK phosphorylation in BV-2 microglial cells
To elucidate the upstream modulator that regulates the StA-mediated activation of Nrf2 in BV-2 microglial cells, various kinase inhibitors, including PKC inhibitor Ro-31-8220, PI3K/ Akt inhibitor LY294002, p38 MAPK inhibitor SB203580, and MEK 1/2 inhibitor U0126 were employed in the following investigation. As shown in Fig. 9 , in the ARE reporter luciferase assay, we found that only pretreatment with MEK 1/2 inhibitor U0126 could significantly suppress StA-induced ARE reporter luciferase activity (Fig. 9A, p < 0.01 ), yet pretreatment of BV-2 microglia with the remaining inhibitors, like, LY294002 (Fig. 9B), SB203580 (Fig. 9C) , or Ro-31-8220 (Fig. 9D) did not inhibit the ARE-luciferase activity (all p > 0.01). Moreover, we observed that only preincubation with U0126 significantly abrogated StA-induced activation of HO-1 in BV-2 cells (Fig. 9E, p < 0.01) . Current results indicated that ERK kinase was involved in StA-induced Nfr2/ARE activation. This result was also consistent with the previously observed phenomenon (showed in Fig. 5B ) of significant StA-induced ERK phosphorylation in BV-2 microglial cells.
Next, we further determined the role of StA in ERK phosphorylation. We found that increases in the phosphorylated forms of ERK were observed from 0.5h after exposure to StA, peaked at 1 to 2 h, and then declined (Fig. 10A , all p < 0.01). Preincubation of U0126 effectively suppressed ERK phosphorylation (Fig. 10B , p < 0.01 versus the control group) and also significantly abolished the StA-induced increase in ERK phosphorylation in BV-2 microglial cells (Fig. 10B , p < 0.01 versus the StA-treated group). Moreover, StA-mediated accumulation of nuclear Nrf2 was totally reversed by U0126 treatment (Fig. 10C , p < 0.01 versus the control group). Further, ERK siRNA was used to knockdown the expression of ERK. As shown in Fig. 10D , ERK siRNA transfection effectively silenced the ERK expression, evidenced by significantly decreased expression of total and phosphorylated ERK in BV-2 cells (both p < 0.01, versus the scramble-siRNA group). As expected, we found that StAinduced ERK phosphorylation and accumulation of nuclear Nrf2 was abolished in ERK siRNA transfected-BV-2 cells (Fig. 10E , p < 0.01, versus the scramble-siRNA group). Cell
Discussion
Neuroinflammatory responses are inevitable and important pathological processes in several types of damage and disorders in the CNS [1] . Microglial activation-mediated inflammatory responses are known to play a crucial role in brain neuroinflammation and subsequent neuronal injuries [1, 2] . Therefore, alleviating activation of the microglia-induced inflammatory process might be a valuable therapeutic approach for neuroinflammationrelated diseases. Since StA was found to be anti-inflammatory and neuroprotective in several reports [22] , this study aimed to investigate whether StA could inhibit microglia-mediated neuroinflammation in LPS-activated BV-2 microglia cells.
The BV-2 microglia cells are well known to be conferred pro-inflammatory properties following LPS stimulation [4] . Initially, we found that StA could suppress both NO/iNOS and PGE 2 /COX-2 signaling pathways in LPS-activated BV-2 microglia. NO and PGE 2 are two crucial mediators of inflammation that are synthesised via iNOS and COX-2, respectively [4] . Moreover, iNOS and COX-2 are mainly expressed by activated glial cells, both of which are also involved in neuronal inflammation and consequently contribute to the pathogenesis of CNS diseases. Thus, compounds that could supress the level of iNOS and COX-2 might be able to prevent and treat neuroinflammation-related CNS disorders. Pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β can promote neuronal damage, and also induce more microglia activation as feedback [23] . Since inflammatory cytokines play a pivotal role in inflammation, modulating cytokine function is key to controlling inflammationinduced CNS disorders [23] . Based on the inhibitory effects of StA on NO/iNOS, PGE 2 /COX-2, pro-inflammatory cytokines, we suggested that StA was able to abate aberrant microglial activation and activated microglial-mediated neuroinflammation.
The NF-κB signalling pathway is well known to be a central regulator of several kinds of inflammatory responses, including microglial-mediated neuroinflammation [5] . Since we previously found that StA could abate pro-inflammatory responses, investigation of the NF-κB pathway might help us to explain the underlying mechanisms further. Firstly, the inhibitory activity of StA against NF-κB transduction was confirmed in reporter gene assay. Next, StAinduced suppression of NF-κB p65 phosphorylation was also found in LPS-stimulated BV-2 microglia. Furthermore, StA inhibited nuclear translocation of NF-κB and attenuated NF-κB-DNA binding activity in LPS-treated BV-2 microglia. All these results demonstrated StA can suppress NF-κB activation in BV-2 cells, consistent with previous reports showing that StAmediated inhibition of NF-κB activity induced anti-inflammatory actions on LPS-stimulated RAW264.7 cells and IL-1β-stimulated human chondrocytes [17] . Furthermore, we then tested the regulatory action of StA on IKK and IκB, two important upstream modulators of NF-κB signal pathways [24] . We found that StA could block not only the phosphorylation of IKKα/β and IκBα, but also the degradation of IκBα in LPS-activated microglia. Therefore, we clearly confirmed inhibitory effects on the activation of IKK and IκB by StA, which results in the inhibition of NF-κB signal pathways. Several classical signaling pathways, like the MAPKs and PI3K/Akt pathways, are involved in NF-κB-mediated neuroinflammation [6, 7, 23] . Activation of MAPKs and Akt can regulate pro-inflammatory responses in microglia by modulating NF-κB signal pathways [13] . MAPKs and PI3K/Akt are also reported to be significantly phosphorylated in LPSstimulated microglia [4, 5, 19] . Previous reports also showed that StA could inhibit the phosphorylation of JNK, p38, ERK, and Akt in response to LPS stimulation in RAW264.7 cells and human chondrocytes [17] . As expected, in the current study, we found that StA could inhibit the phosphorylation of JNK, p38, and Akt induced by LPS in BV-2 microglia. Therefore, we speculated that StA might also suppress these key signal pathways in LPS-activated BV-2 microglial cells, thereby inhibiting NF-κB activity, and subsequently suppressing neuroinflammatory responses.
Accumulating evidence indicates that activated microglia are the major producer of ROS in the CNS [7, 10] . Intracellular ROS acts as an important second messenger in microglialmediated inflammation, which could induce neuronal cell death, subsequently exacerbating disorders of the brain [13, 18] . The elevated ROS level can activate a cascade of harmful events during inflammatory processes, for exmaple via MAPKs, PI3K/Akt, and NF-κB pathways [13] . Moreover, the activation of these ROS-sensitive signaling pathways can further enhance the generation of ROS as a feedback response [13] . Therefore, inhibiting microglial ROS release can protect microglial and neuronal cells against neuroinflammatory damage [7, 10] . In this study, we found that StA could significantly attenuate both the production of microglial ROS and expression of p47 phox, a key component of NADPH oxidase [7, 10] . As expected, these findings were consistent with our previous reports that StA could inhibit intracellular ROS accumulation in neurotoxin-induced SH-SY5Y cells [22] . Taken together, these results suggest that StA-mediated inhibition of ROS production might be a major mechanism of StAinduced anti-neuroinflammation in LPS-activated microglial cells.
Encouraged by the significant inhibition of ROS production by StA in LPS-induced BV-2 cells, we further investigated the antioxidant properties of StA in microglia. Accumulating evidence demonstrates that inducing the activation of antioxidant transcription factor Nrf2, to activate the transcription of genes encoding for endogenous antioxidants, is a promising strategy for decreasing endogenous ROS [7, 9] . In response to oxidative stress, Nrf2 can be dissociated from Keap-1 in the cytosol, and is then translocated into the nucleus, binding to the ARE sequence to activate transcription of antioxidant genes. In current study, we firstly observed StA-induced up-regulation of HO-1 and NQO-1. Importantly, apart from serving as markers of Nrf2 activation, the elevated expression of HO-1 and NQO-1 was also reported to enhance cellular resistance to inflammatory responses. Moreover, we unexpectedly found that HO-1 inhibition obviously decreased the anti-inflammatory action of StA. Therefore, we suggested that StA-induced HO-1 expression was a key mechanism for the potential therapeutic property of StA. Also, we also confirmed the roel of StA on enchancing Nrf2 nuclear translocation, increasing ARE-dependent transcription activity and finally upregulating antioxidant protein expression in LPS-activated BV-2 microglia. Therefore, all of current results totally and fully demonstrated the actions of StA on Nr2 induction. Since that Keap1 was well associated with Nrf2 nuclear translocation, investigations are required to explain the role of Keap1 in StA-mediated Nrf2 activation in our further study.
Recent studies demonstrate that Nrf2 activation contributes to the inhibition of microglial hyperactivation and protection against microgliosis-induced neuronal damage in the brain [7] [8] [9] . Nrf2 activation not only confers anti-oxidative effects but also modulates redox homoeostasis and regulates neuroinflammatory conditions in activated microglial cells [7, 9, 10, 25, 26] . In response to various microenvironments, microglia can polarise into pro-and anti-inflammatory phenotypes [9, 10] . Moreover, more remarkably, activation of Nrf2 pathways has been shown to promote microglial polarisation toward the anti- [27] [28] [29] . On the other hand, Nrf2-deficiency is reported to be more important in inflammatory models [10] . Therefore, induction of Nrf2 signaling pathways by StA might be a valuable strategy for modulating neuroinflammation. In current study, via using the Nrf2 siRNA, we further found that StA-mediated inhibitory actions on LPS-induced pro-inflammatory mediators and cytokines were dependent on Nrf2. Microglial neuroinflammation is well characterised by an elevated level of these pro-inflammatory mediators and cytokines. Therefore, we concluded that StA-mediated Nfr2 induction contributed to its effects on neuroinflammatory responses in LPS-activated BV-2 microglia. The cross-talk between Nrf2 and NF-κB pathways was well reported in previous studies [25, 26, 30] . Firstly, both the Nrf2 and NF-κB pathways coordinate in order to maintain cellular redox homoeostasis [25, 26] . However, phytochemical-induced activation of Nrf2 signaling might have a modulatory effect on activation of NF-κB during neuroinflammation [31] . Moreover, several molecules, as we described above, inhibited NF-κB activation but also activated Nrf2 pathways in microglia [25, 26] . Conversely, accumulating evidence suggests NF-κB activation might directly suppress Nrf2/ARE pathways at transcription levels [25, 26] . In current study, we also observed that, Nrf2 silence also suppressed StA-induced inhibitory effects on NF-κB activity and NF-κB-DNA binding. These observations suggested that StAmediated activation of Nrf2 pathways might contribute to inactivation of NF-κB pathways by StA in LPS-stimulated BV-2 microglia cells. However, the detailed mechanisms underlying this hypothesis require further experiments.
There are two main mechanisms involved in the activation of Nrf2: modification of Keap-1 conformation and phosphorylation of Nrf2 [32] . Some compounds can induce a change in Keap-1 conformation via covalent modification, resulting in the release of Nrf2 from the Nrf2-Keap1 complex [32] . On the other hand, Nrf2 phosphorylation by protein kinases can alter the interaction between Nrf2 and Keap-1 and induce Nrf2 activation [32] . Several protein kinases, including ERK, p38 MAPK, AKT, and PKCδ were reported to be strongly associated with Nrf2 pathways [33] . Interestingly, we found that MEK 1/2 inhibitor U0126 was able to block StA-induced Nrf2 nucleus transactivation, ARE-luciferase activity and HO-1 expression, whereas p38 MAPK, AKT, and PKCδ inhibitors did not abolish StA's actions. Combined with our previous finding that StA induced ERK phosphorylation, we initially considered ERK to be involved in StA-induced Nrf2 activation. ERK signalling is well known to regulate the cell cycle, proliferation, and differentiation; however, it has also been reported to modulate Nrf2-dependent transcription of ARE-related antioxidant genes, in vivo and in vitro [30] . ERK phosphorylation-mediated Nrf2 activation was also found in some well-studied compounds, like lutein [22] and berberine [5, 34] , which could subsequently result in an anti-neuroinflammatory action and neuroprotection in microglial cells. ERK siRNA transfection effectively silenced StA-induced ERK phosphorylation, which totally abolished Nrf2 activation in StA-treated BV-2 microglial cells. Therefore, based on the current results regarding pharmacological inhibiton and gene silencing, we suggest that Nrf2 activation in StA-treated BV-2 cells was mediated by increased ERK phosphorylation by StA.
In summary, this research yielded several principal findings, as follows: (1 
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